Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blinded, placebo-controlled subcutaneously-administered multi-dose Phase 2b trial of ANB020 in moderate-to-severe baseline adult peanut allergy patients

Next Previous
Trial Profile

A randomized, double-blinded, placebo-controlled subcutaneously-administered multi-dose Phase 2b trial of ANB020 in moderate-to-severe baseline adult peanut allergy patients

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etokimab (Primary)
  • Indications Peanut hypersensitivity
  • Focus Therapeutic Use

Most Recent Events

  • 07 Aug 2018 According to an AnaptysBio media release, the company has decided to deprioritize further the company-sponsored clinical development of Etokimab in peanut allergy patients, as , the company is not intent to use its resources to pursue a Phase 2b clinical trial of etokimab in peanut allergy.
  • 08 May 2018 According to an AnaptysBio media release, the Company anticipates that severity symptoms of all patients in the trial will be adjudicated during baseline and post-treatment oral food challenges by an independent, blinded assessor in accordance with PRACTALL guidelines, and any patients that demonstrate mild severity of symptoms at baseline will be excluded from enrollment in the trial.
  • 02 Apr 2018 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top